Comparative Pharmacology
Head-to-head clinical analysis: ADMELOG versus HUMALOG MIX 50 50.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADMELOG versus HUMALOG MIX 50 50.
ADMELOG vs HUMALOG MIX 50/50
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Insulin lispro is a rapid-acting insulin analog that binds to the insulin receptor, activating downstream signaling pathways to facilitate cellular glucose uptake, inhibit hepatic gluconeogenesis, and promote glycogen synthesis, lipogenesis, and protein synthesis.
Insulin analog that binds to insulin receptors, activating downstream signaling pathways to promote glucose uptake, glycogen synthesis, and lipogenesis, and inhibit gluconeogenesis and ketogenesis.
Subcutaneous injection: 0.2-1.0 units/kg/day divided into 2-4 doses. Typical starting dose: 0.4-0.6 units/kg/day. Administer within 15 minutes before or immediately after a meal.
Subcutaneous injection of 0.2 to 0.6 units/kg/day divided into 3 or more doses, with the preprandial dose based on blood glucose monitoring. Typical total daily dose is 0.5 units/kg/day. Administer within 15 minutes before or after a meal.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5-2.5 hours (subcutaneous administration). This short half-life reflects rapid absorption and clearance, suitable for prandial glucose control.
Subcutaneous injection: terminal half-life approximately 1-2 hours, reflecting clearance from the injection site and systemic elimination. Clinical context: allows twice-daily dosing.
Renal (primarily as unchanged drug, following degradation by insulin-degrading enzyme). Approximately 60-80% of a dose is excreted renally; the remainder is metabolized in the liver and kidneys.
Primarily via renal excretion of insulin degradation products; less than 1% excreted as unchanged insulin. No significant biliary or fecal elimination.
Category C
Category C
Insulin
Insulin